NCT02578095

Acute Hip Fracture Study in Patients 65 Years or Greater

A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Viking Therapeutics, Inc. · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment. Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be eligible for participation 3-7 weeks post-injury.

Conditions

• Hip Fractures

Interventions

Type	Name	Description
DRUG	VK5211	Capsule
DRUG	Placebo	Capsule

Timeline

• Start date: 2015-10-30
• Primary completion: 2017-11-15
• Completion: 2017-12-17
• First posted: 2015-10-16
• Last updated: 2025-12-29
• Results posted: 2025-12-29

Locations

21 sites across 4 countries: United States, Hungary, Romania, Serbia